Impact News +++ GoldQuest Mining Corp.: GoldQuest Closes Third and Final Tranche of Private Placement for Gross Proceeds of... (Newsfile) +++ GOLDQUEST Aktie +3,52%

MESOBLAST Aktie

>MESOBLAST Aktienkurs

1.56 EUR -4.9% (Tradegate)

Ask: 1.61 EUR / 1236 Stück

Bid: 1.52 EUR / 1317 Stück

Tagesumsatz: 1016 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

MESOBLAST Aktie über LYNX handeln

Intraday

1 Jahr

>MESOBLAST Performance

1 Woche: +2,6%

1 Monat: -0,3%

3 Monate: -1,6%

6 Monate: +67,7%

1 Jahr: -4,9%

laufendes Jahr: +3,7%

>MESOBLAST Aktie

Name:

MESOBLAST LTD.

Land:

Australien

Sektor:

Gesundheit

ISIN/ Wkn:

AU000000MSB8 / A0DNPW

Symbol/ Ticker:

LWB (Frankfurt)

Kürzel:

FRA:LWB, ETR:LWB, LWB:GR

Index:

Webseite:

https://www.mesoblast.com..

Profil:

Mesoblast Limited is a biotechnology company speci..
>Volltext..

Marktkapitalisierung:

2105.12 Mio. EUR

Unternehmenswert:

2076.63 Mio. EUR

Umsatz:

15.2 Mio. EUR

EBITDA:

-49.3 Mio. EUR

Nettogewinn:

-89.2 Mio. EUR

Gewinn je Aktie:

-0.07 EUR

Schulden:

110.42 Mio. EUR

Liquide Mittel:

139.2 Mio. EUR

Operativer Cashflow:

-50.35 Mio. EUR

Bargeldquote:

1.57

Umsatzwachstum:

167.82%

Gewinnwachstum:

-5.68%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

MESOBLAST

Letzte Datenerhebung:

14.01.26

>MESOBLAST Kennzahlen

Aktien/ Unternehmen:

Aktien: 1282.94 Mio. St.

Frei handelbar: 66.46%

Leerverk. Aktien: -

Rückkaufquote: -6.92%

Mitarbeiter: 81

Umsatz/Mitarb.: 0.19 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 57.45%

Bewertung:

KGV: -

KGV lG: -

KUV: 140.59

KBV: 3.85

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 29.47%

Gewinnmarge: -587.03%

Operative Marge: -361.46%

Managementeffizenz:

Gesamtkaprendite: -14.37%

Eigenkaprendite: -19.37%

>MESOBLAST Peer Group

Es sind 56 Aktien bekannt.

>MESOBLAST Chart & Kurs - Tradegate

>MESOBLAST News

09.01.26 - 23:00	Markets in a Minute: Mesoblast, Alkane Resources shine (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

09.01.26 - 19:09	Mesoblast rises as Ryoncil sales climb 60% in December quarter (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

09.01.26 - 04:30	Mesoblast back to record highs as Ryoncil sales jump 60% QoQ to US$35M (Market Herald)
	Mesoblast (ASX:MSB) is back onto investors' radars after the slower Christmas period,…...

09.01.26 - 03:24	Why Codan, DroneShield, Mesoblast, and Woodside shares are storming higher today (Fool)
	These shares are ending the week strongly. But why? The post Why Codan, DroneShield, Mesoblast, and Woodside shares are storming higher today appeared first on The Motley Fool Australia....

09.01.26 - 01:01	Why are Mesoblast shares jumping 10% to a 52-week high? (Fool)
	This biotech is hitting new highs on Friday. Let's find out why. The post Why are Mesoblast shares jumping 10% to a 52-week high? appeared first on The Motley Fool Australia....

02.01.26 - 00:06	Mesoblast Announces Changes to Board of Directors′ Leadership Roles (GlobeNewswire EN)
	NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at the recent Annual General Meeting the Board will undertake a number of changes in line with the Company's evolution to a revenue-generating commercial company....

30.12.25 - 03:12	Why DroneShield, IPD, Mesoblast, and Woodside shares are charging higher today (Fool)
	These shares are having a good session on Tuesday. Let's see why. The post Why DroneShield, IPD, Mesoblast, and Woodside shares are charging higher today appeared first on The Motley Fool Australia....

30.12.25 - 02:36	This ASX healthcare stock just changed its debt. Here′s why it matters (Fool)
	Shares in Mesoblast edge higher after the company announces a major change to its debt and funding structure. The post This ASX healthcare stock just changed its debt. Here's why it matters appeared first on The Motley Fool Australia....

30.12.25 - 01:00	Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line (GlobeNewswire EN)
	Mesoblast has option to draw down up to US$125 million by June 30, 2026...

24.12.25 - 01:30	Mesoblast, Invictus, PLS Group, more: The 10 stocks that got investor chins wagging on HotCopper in CY25 (Market Herald)
	With more than seven million users moving through HotCopper forums every year,…...

12.12.25 - 00:27

Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD (GlobeNewswire EN)

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent peer-reviewed comparative analysis of efficacy and safety between remestemcel-L and ruxolitinib for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) was presented at the 67th ASH Annual meeting in Florida this past week. The independent study authors concluded that remestemcel-L showed superior outcomes in complete and overall remission compared with ruxolitinib.1...

09.12.25 - 21:00	How much further upside is there for Mesoblast shares after soaring 23% in a month? (Fool)
	Could FDA approval send this healthcare stock towards further gains? The post How much further upside is there for Mesoblast shares after soaring 23% in a month? appeared first on The Motley Fool Australia....

04.12.25 - 00:15	Mesoblast Participation at Piper Sandler Conference (GlobeNewswire EN)
	NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at the Piper Sandler 37th Annual Healthcare Conference in New York on December 2–4, 2025....

27.11.25 - 04:24	Mesoblast shares: bull vs. bear (Fool)
	Two experts have presented their case for buying and selling the ASX biotech stock. The post Mesoblast shares: bull vs. bear appeared first on The Motley Fool Australia....

25.11.25 - 01:36	Mesoblast shares push higher on strong sales update (Fool)
	Sales are growing for this biotech. Let's see what it reported today. The post Mesoblast shares push higher on strong sales update appeared first on The Motley Fool Australia....

25.11.25 - 00:42	Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue (GlobeNewswire EN)
	NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided a trading update, together with a comprehensive operational overview, as part of the Chief Executive's Annual General Meeting (AGM) address....

24.11.25 - 05:48	Should you buy Mesoblast, Paladin Energy, and Xero shares? (Fool)
	Analysts have given their verdicts on these shares. The post Should you buy Mesoblast, Paladin Energy, and Xero shares? appeared first on The Motley Fool Australia....

21.11.25 - 00:36

Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids (GlobeNewswire EN)

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high rate of non-responsiveness to therapies in adults with severe acute graft versus host disease (aGvHD) who fail corticosteroids, and the high mortality in these patients, Mesoblast and the United States National Institutes of Health (NIH)-funded Blood and Marrow Transplant Clinical Trials Network (BMT CTN) will collaborate on a pivotal trial of Ryoncil® (remestemcel-L-rknd) as part of first-line regimen in adults with severe aGvHD refractory to corticosteroids (SR-aGvHD). The BMT CTN is a body representing U.S. centers responsible for performing approximately 80% of all U.S. allogeneic BMTs....

18.11.25 - 05:36	Brokers say Mesoblast, NAB, and Pilbara Minerals shares are sells (Fool)
	These shares have been hit with sell ratings. But why? The post Brokers say Mesoblast, NAB, and Pilbara Minerals shares are sells appeared first on The Motley Fool Australia....

17.11.25 - 08:36	Mesoblast appoints James M. O’Brien as US-based CFO (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Man muß seine Feinde kennen. Ihre Verbündeten und die Natur ihres Landes, um einen Feldzug planen zu können. - König Friedrich II.

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram